SOTORASIB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 353 adverse event reports in the FDA FAERS database where SOTORASIB was used for Lung neoplasm malignant.
Most Reported Side Effects for SOTORASIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Non-small cell lung cancer | 483 | 16.5% | 131 | 55 |
| Death | 319 | 10.9% | 311 | 19 |
| Disease progression | 314 | 10.7% | 83 | 9 |
| Diarrhoea | 284 | 9.7% | 39 | 62 |
| Off label use | 193 | 6.6% | 41 | 22 |
| Nausea | 98 | 3.4% | 16 | 27 |
| Non-small cell lung cancer metastatic | 93 | 3.2% | 33 | 16 |
| Hepatotoxicity | 91 | 3.1% | 16 | 16 |
| Fatigue | 87 | 3.0% | 5 | 14 |
| Hepatic function abnormal | 80 | 2.7% | 12 | 27 |
| Aspartate aminotransferase increased | 71 | 2.4% | 6 | 19 |
| Alanine aminotransferase increased | 70 | 2.4% | 5 | 17 |
| Lung neoplasm malignant | 64 | 2.2% | 17 | 8 |
| Drug ineffective | 62 | 2.1% | 8 | 5 |
| Decreased appetite | 56 | 1.9% | 11 | 16 |
Other Indications for SOTORASIB
Non-small cell lung cancer (897)
Product used for unknown indication (850)
K-ras gene mutation (752)
Non-small cell lung cancer stage iv (159)
Lung adenocarcinoma (104)
Non-small cell lung cancer metastatic (70)
Lung adenocarcinoma stage iv (39)
Colorectal cancer metastatic (35)
Off label use (33)
Non-small cell lung cancer recurrent (28)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)